Reuters logo
BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis
2017年3月22日 / 晚上8点18分 / 6 个月前

BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis

March 22 (Reuters) - Alexion Pharmaceuticals Inc -

* Alexion submits application in Japan for soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below